Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb randomized study of certolizumab pegol in Crohn's disease: hospital vs at-home administration
2007-003239-21Phase 3Active
- Sponsor
- UCB
- Start
- Jan 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of certolizumab pegol in Crohn's disease (2 arms), sponsored by UCB. Primary endpoint: Clinical response rate at week 6. Started Jan 2008; status: active.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2007-003239-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003239-21.